Clinical Trials Logo

Hepatic Metastases clinical trials

View clinical trials related to Hepatic Metastases.

Filter by:

NCT ID: NCT03728543 Not yet recruiting - Anesthesia Clinical Trials

the Efficacy and Safety of Sugammadex in Children 0-2 Years Old

Start date: November 15, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Sugammadex is a selective antidote to muscle relaxants rocuronium bromide and vecuronium bromide. Sugammadex is a modified gamma-cyclodextrin, a compound that selectively binds rocuronium bromide and vecuronium bromide. It forms a complex with them in the blood plasma, which leads to the decrease in the concentration of muscle relaxant binding to nicotinic receptors in the neuromuscular synapse. The result is the the elimination of neuromuscular blockade caused by rocuronium bromide or vecuronium bromide. Sugammadex is used to eliminate neuromuscular blockade caused by rocuronium bromide in children aged 2 years and adolescents in standard clinical situations. The aim of the study is to prove the efficacy and safety of sugammadex in children under 2 years

NCT ID: NCT03458975 Completed - Colorectal Cancer Clinical Trials

Targeted Delivery of Chemotherapy With Ultrasound and Microbublles

SONCHIMIO
Start date: October 1, 2019
Phase: Phase 2
Study type: Interventional

The oscillations of ultrasound (US) contrast agent microbubbles under their activation by US waves engender a modulation of the permeability of biological barriers amplifying hence the extravasation of drugs and/or fluorescent markers through a process known as sonoporation. In such a way, the bioavailability of the therapeutic agent is augmented only in the area where US waves are focused. The objective now is to translate this therapeutic approach to the clinic by performing a feasibility study with the development of a therapy regime optimized for hepatic metastases of colorectal cancer. In order to demonstrate the clinical feasibility of the therapeutic approach based on ultrasound and microbubbles, we will focus on patients with liver metastases of colorectal cancer treated with monoclonal antibodies in combination with chemotherapy.

NCT ID: NCT03369041 Active, not recruiting - Clinical trials for Colorectal Adenocarcinoma

Study of the Practice of Debiri in France

Start date: February 3, 2016
Phase:
Study type: Observational [Patient Registry]

In order to extract the profiles of patients receiving DEBIRI treatment at best, the investigators proposed the establishment of a national prospective cohort to collect information on the greatest number of patients treated with DEBIRI. This cohort will allow a better understanding of the effectiveness, tolerance, feasibility and differences of practices at national level for this approach. These data will assist in the development of clinical trials in situations that appear to be most promising in clinical practice.

NCT ID: NCT03364621 Active, not recruiting - Colorectal Cancer Clinical Trials

Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy

COMPARISON
Start date: August 29, 2017
Phase:
Study type: Observational

This is a prospective study investigating the disease course of patients with colorectal cancer that have had their cancer spread to their liver. The aim of this study is find potential biomarkers for disease recurrence and therapeutic targets for prognostic information.

NCT ID: NCT03297463 Withdrawn - Metastatic Melanoma Clinical Trials

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Start date: January 31, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2 study designed to evaluate combination of the human T-cell cytokine Interleukin-2 (IL-2) and a checkpoint inhibitor Ipilimumab immediately following a course of hypofractionated palliative radiation therapy in the management of unresectable, relapsed/refractory metastatic melanoma.

NCT ID: NCT02913417 Active, not recruiting - Uveal Melanoma Clinical Trials

Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

Start date: October 10, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Reports to date show limited efficacy of immunotherapy for uveal melanoma. Recent experimental and clinical evidence suggests synergy between radiation therapy and immunotherapy. The investigators will explore this synergy with a feasibility study of 26 patients with uveal melanoma and hepatic metastases who will receive SirSpheres Yttrium-90 selective internal hepatic radiation followed by immunotherapy with the combination of ipilimumab and nivolumab.

NCT ID: NCT01678664 Completed - Clinical trials for Neuroendocrine Tumors

Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors

EVACEL
Start date: October 2012
Phase: Phase 2
Study type: Interventional

Determine wether 24 months treatment with everolimus prolongs progression free survival rate (based on a central assessment) after embolisation ou chemoembolisation for liver metastases. - H0 a 24 months progression free survival rate less than 35% is unacceptable - H1 a 24 months progression free survival rate greater than 35% would show that everolimus treatment is beneficial, the expected 24 months progression free survival rate being 50%

NCT ID: NCT01073358 Enrolling by invitation - Colorectal Cancer Clinical Trials

Resection of Colorectal Liver Metastases With or Without Routine Hilar Lymphadenectomy

RELY
Start date: March 9, 2010
Phase: N/A
Study type: Interventional

It is uncertain, whether hilar lymphadenectomy should be performed routinely in patients undergoing resection of colorectal liver metastases. For this reason it is the aim of the present prospective randomized trial to evaluate, if routine lymphadenectomy reduces recurrent disease in patients undergoing resection of colorectal liver metastases.

NCT ID: NCT00465023 Completed - Cholangiocarcinoma Clinical Trials

Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases

Start date: June 2003
Phase: N/A
Study type: Interventional

The main purpose of this study is to determine if high doses of radiation using proton beam can be given safely with low and acceptable side effects. We will also gather information to determine the ability of proton beam to destroy cancer cells in the liver. There are two types of external radiation treatments (proton beam and photon beam). Proton beam radiation is a very accurate kind of treatment that has been shown to affect less normal tissue than a regular radiation beam. The accuracy allows us to more safely increase the amount of radiation delivered to eliminate cancer and may potentially reduce the side effects normally experienced with standard radiation therapy.

NCT ID: NCT00264979 Terminated - Colorectal Cancer Clinical Trials

Evaluation of 2 Resection Strategies of Synchronous Colorectal Cancer Metastases

METASYNC
Start date: March 2, 2006
Phase: N/A
Study type: Interventional

The surgical strategy for the treatment of synchronous colorectal cancer liver metastases has not still been defined. The purpose of this study is to compare two treatment strategies in which liver resection is performed either during, or 12 to 14 weeks after the primary resection. Endpoints include the rate of severe complications and survival.